SEC Form 4 · accession 0001140361-17-038269
AVADEL PHARMACEUTICALS PLC · AVDL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marcus W Elrod
Other
Period of report
Oct 10, 2017
Accepted (ET)
Oct 11, 2017 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001012477
Table I — non-derivative securities
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $13.59 | holding | — | — | — | — | Aug 10, 2026 | ADSs | 100,000 | 100,000 | D |
| Stock Option (right to buy)F4 | $10.40 | holding | — | — | — | — | Dec 14, 2026 | ADSs | 22,000 | 22,000 | D |
Explanation of responses
- F1The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- F2Represents 3,400 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
- F3Options become exercisable as to 25,000 ADSs on each of August 10, 2017, 2018, 2019 and 2020, provided that the reporting person continues to be employed by the issuer or an affiliate thereof.
- F4Options become exercisable as to 5,500 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Remarks
This filing constitutes a Form 4 exit filing for the Reporting Person as the Reporting Person is no longer subject to Section 16 under the Securities Exchange Act of 1934.